Kjell E. Oberg

Q: What Schools Are Affiliated With Kjell E. Oberg

Kjell E. Oberg is affiliated with the following schools: Uppsala University, Sapienza University of Rome

Kjell E. Oberg's AcademicInfluence.com Rankings

Kjell E. Oberg

Philosophy

#6690

World Rank

#9771

Historical Rank

Logic

#3818

World Rank

#5030

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Kjell E. Oberg's Degrees

Doctorate Medicine Uppsala University
PhD Medicine Uppsala University

Why Is Kjell E. Oberg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kjell E. Oberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Gastroenteropancreatic neuroendocrine tumours. (2008) (1504)
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. (2004) (561)
Endocrine tumours of the pancreas. (2005) (517)
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. (2015) (501)
Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. (1991) (482)
Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. (1997) (447)
Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set (2010) (321)
Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. (2003) (310)
Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. (1990) (294)
90Y-edotreotide for metastatic carcinoid refractory to octreotide. (2010) (292)
Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. (1995) (291)
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. (2011) (290)
Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. (1983) (269)
Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. (1988) (253)
Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. (1986) (249)
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. (2018) (226)
Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. (1993) (224)
Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. (1991) (223)
Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. (1999) (221)
Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. (1992) (211)
Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. (1993) (206)
Consensus on biomarkers for neuroendocrine tumour disease. (2015) (203)
A comparison between three commercial kits for chromogranin A measurements. (2003) (203)
Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. (2003) (195)
High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. (1997) (181)
Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. (2010) (181)
'Satisfaction with care': associations with health-related quality of life and psychosocial function among Swedish patients with endocrine gastrointestinal tumours. (2002) (180)
Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. (2000) (179)
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. (2012) (175)
Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results. (1986) (174)
Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. (1993) (165)
Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. (1999) (162)
Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (157)
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. (2007) (156)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification (2017) (156)
Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. (2005) (153)
Neuropeptide K: a major tachykinin in plasma and tumor tissues from carcinoid patients. (1985) (146)
Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. (1998) (145)
An update of the medical treatment of malignant endocrine pancreatic tumors. (1993) (139)
Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1. (1987) (138)
Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. (1992) (135)
High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. (2004) (134)
Experience in treatment of metastatic pulmonary carcinoid tumors. (2001) (130)
Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism. (1999) (129)
Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients. (1989) (126)
The role of interferons in the management of carcinoid tumors. (1991) (124)
Expression and prognostic significance of Bcl-2 in ovarian tumours. (1995) (123)
Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. (1997) (122)
Pancreatic neuroendocrine tumors: diagnosis with PET. (1995) (122)
Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. (1992) (120)
Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. (2005) (119)
Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. (1989) (118)
Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids. (1996) (116)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers (2017) (116)
Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush. (1986) (115)
Localization of the genetic defect in multiple endocrine neoplasia type 1 within a small region of chromosome 11. (1989) (113)
Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. (2001) (108)
Adrenal lesion in multiple endocrine neoplasia type 1. (1995) (108)
Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. (1998) (108)
Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. (1993) (107)
Malignant gastric ghrelinoma with hyperghrelinemia. (2004) (105)
[111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. (1994) (102)
p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. (1994) (99)
Multiple endocrine neoplasia type 1. Clinical features and screening. (1994) (98)
Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management (2010) (97)
Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. (1995) (96)
Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. (2002) (96)
A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: five years experience. (1987) (95)
Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. (1998) (94)
Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. (1999) (93)
Developments in PET for the detection of endocrine tumours. (2005) (93)
Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? (2006) (92)
Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. (1998) (91)
Prognostic markers in patients with typical bronchial carcinoid tumors. (2000) (91)
Interferon in the management of neuroendocrine GEP-tumors: a review. (2000) (91)
Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin--alone or in combination with 5-FU. (1987) (89)
Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (87)
Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. (2000) (86)
Menin's interaction with glial fibrillary acidic protein and vimentin suggests a role for the intermediate filament network in regulating menin activity. (2002) (85)
Chromogranins--new sensitive markers for neuroendocrine tumors. (1989) (85)
Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. (1991) (84)
Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. (2008) (81)
A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours. (1990) (81)
Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. (1990) (80)
Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments. (1993) (80)
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management (2016) (80)
Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide. (1993) (79)
Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches (2013) (78)
hCG and hCG subunits as tumour markers in patients with endocrine pancreatic tumours and carcinoids. (1981) (76)
A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. (1992) (76)
Neuroendocrine Tumor Biomarkers: Current Status and Perspectives (2014) (76)
In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine. (1996) (74)
Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon. (1989) (74)
Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. (2001) (74)
Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. (1992) (73)
Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. (1994) (73)
Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. (2000) (72)
Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors. (2000) (71)
Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. (2001) (71)
Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors. (1991) (70)
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects (2015) (69)
Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumours (1990) (69)
Midgut carcinoid tumours. CT appearance. (1995) (66)
Medical treatment of neuroendocrine gut and pancreatic tumors. (1989) (65)
Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. (1995) (61)
Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). (2009) (60)
Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors--evaluation of therapeutic and toxic effects. (1999) (60)
Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. (2006) (59)
The pentagastrin test in the diagnosis of the carcinoid syndrome. Blockade of gastrointestinal symptoms by ketanserin. (1985) (58)
Treatment, prognostic markers and survival in thymic neuroendocrine tumours. a study from a single tertiary referral centre. (2013) (57)
Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors. (1994) (57)
Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. (2004) (56)
Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. (1993) (55)
Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours. (2001) (54)
The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours. (1996) (54)
Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas. (1997) (53)
Chemotherapy and biotherapy in neuroendocrine tumors. (1993) (53)
Survival and daily physical activity in patients treated for advanced midgut carcinoid tumors. (1997) (53)
Neuroendocrine Neoplasms of the Small Bowel and Pancreas (2019) (52)
Neuroendocrine gastrointestinal tumours. (1996) (52)
Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. (1991) (50)
Peptide hormone markers in screening for endocrine tumors in multiple endocrine adenomatosis type I. (1982) (50)
A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. (1996) (50)
Neuroendocrine gastrointestinal tumors--a condensed overview of diagnosis and treatment. (1999) (50)
Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. (2011) (49)
Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment. (2005) (49)
Tumour markers in neuroendocrine tumours. (1999) (49)
Gastrointestinal carcinoid tumours. Histogenetic, histochemical, immunohistochemical, clinical and therapeutic aspects. (1989) (48)
Multiple endocrine neoplasia type 1 (MEN-1). Clinical, biochemical and genetical investigations. (1989) (48)
The management of neuroendocrine tumours: current and future medical therapy options. (2012) (48)
Combination of Cross-Sectional and Molecular Imaging Studies in the Localization of Gastroenteropancreatic Neuroendocrine Tumors (2014) (47)
Surgical treatment of carcinoid heart disease. (1990) (46)
Effects of interferon on tumor tissue content in liver metastases of human carcinoid tumors. (1990) (46)
Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors. (2004) (46)
Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography. (2000) (45)
Different splice variants of CD44 are expressed in gastrinomas but not in other subtypes of endocrine pancreatic tumors. (1994) (44)
The pentagastrin test in the diagnosis of the carcinoid syndrome. (1985) (43)
Percutaneous ultrasonography-guided cutting biopsy from liver metastases of endocrine gastrointestinal tumors. (1987) (43)
The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro. (2010) (42)
Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours. (1999) (41)
Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours. (2000) (39)
Cyclofenil versus placebo in progressive systemic sclerosis. A one-year double-blind crossover study of 27 patients. (2009) (37)
Transoesophageal echocardiography improves the diagnostic value of cardiac ultrasound in patients with carcinoid heart disease. (1990) (37)
The action of interferon alpha on human carcinoid tumours. (1992) (37)
Expression of growth factors and their receptors in neuroendocrine gut and pancreatic tumors, and prognostic factors for survival. (1994) (37)
Characterisation of a cell line (LCC-18) from a cultured human neuroendocrine-differentiated colonic carcinoma. (1991) (36)
The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome. (1989) (34)
Isolation and characterization of neurokinin A, neurokinin A(3-10) and neurokinin A(4-10) from a neutral water extract of a metastatic ileal carcinoid tumour. (1987) (34)
Biochemical diagnosis of neuroendocrine GEP tumor. (1997) (34)
Pasireotide ( SOM 230 ) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR : results from a phase II study (2012) (33)
Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trial. (1993) (33)
Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers. (1994) (33)
State of the art and future prospects in the management of neuroendocrine tumors. (2000) (33)
Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches. (2012) (32)
Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines. (2006) (31)
Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. (2008) (31)
Demonstration of high monoaminoxidase-A levels in neuroendocrine gastroenteropancreatic tumors in vitro and in vivo-tumor visualization using positron emission tomography with 11C-harmine. (2003) (31)
Diagnosis and treatment of carcinoid tumors. (2003) (31)
Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. (1987) (30)
Motilin in plasma and tumor tissues from patients with the carcinoid syndrome. Possible involvement in the increased frequency of bowel movements. (1987) (30)
Expression of p68 protein kinase and its prognostic significance during IFN-alpha therapy in patients with carcinoid tumours. (1998) (30)
Effects of Interferon Alpha on the Expression of p21cip1/waf1 and Cell Cycle Distribution in Carcinoid Tumors (2002) (30)
NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging (2019) (30)
Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (29)
Cancer: Antitumor effects of octreotide LAR, a somatostatin analog (2010) (28)
The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors (2019) (28)
Update on pancreatic polypeptide as a specific marker for endocrine tumours of the pancreas and gut. (2009) (28)
The use of chemotherapy in the management of neuroendocrine tumors. (1993) (27)
Interferons in the management of neuroendocrine tumors and their possible mechanism of action. (1992) (27)
A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. (2011) (26)
Quality of life in patients with multiple endocrine neoplasia type 1 (MEN 1). (2003) (25)
Antibodies to Interferon-α in Treated Cancer Patients: Incidence and Significance (1997) (25)
An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis (2019) (25)
Islet amyloid polypeptide-producing pancreatic islet cell tumor. A clinical and biochemical characterization. (1992) (25)
Interferon Alpha Induction of Stat1 and Stat2 and Their Prognostic Significance in Carcinoid Tumors (2001) (24)
Management of neuroendocrine tumours. (2004) (24)
NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease (2018) (24)
Gastric neuroendocrine cells and secretory products. (1998) (24)
Hypersecretion of calcitonin in patients with the Verner-Morrison syndrome. (1981) (24)
Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors. (1999) (23)
Endocrine tumors of the gastrointestinal tract: systemic treatment. (1994) (23)
Interferon-mediated in vivo induction of beta 2-microglobulin on small-cell lung cancers and mid-gut carcinoids. (1986) (23)
Tachykinin production by carcinoid tumours in culture. (1987) (23)
The interferon-alpha regulation of interferon regulatory factor 1 (IRF-1) and IRF-2 has therapeutic implications in carcinoid tumors. (2000) (23)
Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer (2016) (21)
Inhibition of CDK2, CDK4 and cyclin E and increased expression of p27Kip1 during treatment with interferon-alpha in carcinoid tumor cells. (1999) (21)
Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon. (1983) (20)
Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumours. (2000) (20)
Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. (2008) (20)
Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest) (2021) (20)
Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1. (2005) (20)
Interferon-alpha versus somatostatin or the combination of both in gastro-enteropancreatic tumours. (1996) (20)
Treatment of neuroendocrine tumors. (1994) (19)
Established clinical use of octreotide and lanreotide in oncology. (2001) (19)
Advances in chemotherapy and biotherapy of endocrine tumors. (1998) (19)
Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment. (2003) (19)
Streptozotocin treatment of a pancreatic tumour producing VIP and gastrin associated with Verner-Morrison syndrome. (2009) (19)
Cytogenetical investigations in patients with primary hyperparathyroidism and multiple endocrine neoplasia type 1. (2008) (18)
Treatment of malignant endocrine pancreatic tumors with a new long-acting somatostatin analogue, SMS 201-995. (1988) (18)
Pancreatic endocrine tumors. (2010) (17)
Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment. (1992) (16)
Serum growth hormone in patients with carcinoid tumours; basal levels and response to glucose and thyrotrophin releasing hormone. (1985) (16)
Plasma atrial natriuretic peptide in carcinoid heart disease. (1989) (16)
Histochemical and immunohistochemical morphology of carcinoid heart disease. (1991) (15)
Differentially expressed cDNAs in PLCbeta3-induced tumor suppression in a human endocrine pancreatic tumor cell line: activation of the human mismatch repair protein 3 gene. (2001) (15)
Interferon-alpha induces bcl-2 proto-oncogene in patients with neuroendocrine gut tumor responding to its antitumor action. (1997) (14)
Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors. (2009) (14)
Scintigraphy using a 111indium-labeled somatostatin analogue for localization of neuroendocrine tumors (1992) (14)
Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors. (1989) (14)
Genetic and clinical characteristics of multiple endocrine neoplasia type 1. (1991) (14)
Nuclear DNA distribution in neuroendocrine gastroenteropancreatic tumors before and during treatment. (1989) (13)
A Multigenomic Liquid Biopsy Biomarker for Neuroendocrine Tumor Disease outperforms CgA and has Surgical and Clinical Utility. (2021) (13)
Characterization of three peptides derived from prosomatostatin [prosomatostatin-(1-63)-, -(65-76)- and -(79-92)-peptides] in a human pancreatic tumour. (1987) (13)
Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs). (2012) (13)
NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis. (2020) (12)
Nonantral gastric carcinoid tumours associated with hypergastrinaemia. (2009) (12)
Diagnostic criteria of classical carcinoids. (1991) (12)
Interferon-induced nuclear DNA alterations in malignant carcinoid tumors in vivo. (1986) (12)
Malignant neuroendocrine tumors. (2002) (12)
Relative proton density and relaxation times in liver metastases during interferon treatment. (1989) (12)
Subcellular Distribution of Phospholipase C Isoforms in Rodent Pancreas and Gastric Mucosa. (2000) (11)
Neuroendocrine tumors (NETs): historical overview and epidemiology. (2010) (11)
Gastric carcinoid in a patient infected with Helicobacter pylori: a new entity? (2011) (11)
In vitro culture of neuroendocrine tumors of the pancreas and gut. (1989) (11)
Hyperparathyroidism of multiple endocrine neoplasia type 1: candidate gene and parathyroid calcium sensing protein expression. (1995) (11)
Antibodies to interferon-alpha in treated cancer patients: incidence and significance. (1997) (11)
Three-dimensional OctreoScan111 SPECT of abdominal manifestation of neuroendocrine tumours. (1993) (10)
Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results. (2011) (10)
Texture analysis of medical images in radiotherapy (2016) (9)
In vivo cellular distribution and endocytosis of the somatostatin receptor-ligand complex. (1999) (9)
The ultimate biochemical diagnosis of gastro-enteropancreatic tumours. (1996) (9)
Neurotensinlike immunoreactivity in plasma and tumor tissue from patients with endocrine tumors of the pancreas and gut. (1983) (9)
Oncolytic viruses for the treatment of neuroendocrine tumors. (2011) (9)
Somatostatin receptor ligands and their use in the treatment of endocrine disorders. (1999) (9)
In situ RNA-RNA hybridisation of phospholipase C beta 3 shows lack of expression in neuroendocrine tumours. (2003) (8)
Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms (2019) (8)
Chromogranin A and B in neuronal elements in Hirschsprung's disease: an immunocytochemical and radioimmunoassay study. (1994) (8)
Prospective screening in multiple endocrine neoplasia type 1. (1992) (8)
Is it time to widen the use of somatostatin analogs in neuroendocrine tumors? (2009) (8)
Biological aspects of neuroendocrine gastro-enteropancreatic tumours. (1996) (8)
Molecular cloning and characterization of a cDNA encoding the rat interleukin-8 receptor. (1997) (7)
Adrenal gland surgery. Preoperative location of lesions, histologic findings and outcome of surgery. (1986) (7)
Does alpha-interferon in conjunction with radiotherapy increase the risk of complications in the central nervous system? (1990) (7)
Cyclofenil in the treatment of scleroderma - a general view on the results after treating 29 cases. (1980) (6)
Biology, diagnosis, and treatment of neuroendocrine tumors of the gastrointestinal tract. (1994) (6)
Histogenesis of a duodenal carcinoid. (1989) (6)
Silver stains and immunocytochemical analysis with monoclonal serotonin antibodies for liver metastases of endocrine tumors. A study on percutaneous biopsy specimens. (1984) (6)
Application of silver stains to cytologic specimens of neuroendocrine tumors metastatic to the liver. (1985) (6)
Effect of 6-diazo-5-oxo-L-norleucine (DON) on human carcinoid tumor cell aggregates. (1997) (6)
Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours (2021) (6)
Severe systemic vasoconstriction starting with acute limb ischemia leading to death in a patient with well-differentiated pulmonary neuroendocrine carcinoma: A new paraneoplastic syndrome? (2012) (6)
Effects of secretin on parathyroid hormone and calcium in normal subjects, patients with hyperparathyroidism and patients with gastrinoma. (2009) (6)
The cytotoxic effect of emetine and CGP-74514A studied with the hollow fiber model and ArrayScan assay in neuroendocrine tumors in vitro. (2012) (6)
Effect of interferon on T1 relaxation times of liver metastases from endocrine gastrointestinal tumours. (1988) (6)
Efficacy and safety of telotristat ethyl in patients With carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period. (2017) (5)
Treatment of neuroendocrine gut and pancreatic tumors with interferons. (1989) (5)
Transmembrane protein tyrosine phosphatase IA-2 (ICA512) is expressed in human midgut carcinoids but is not detectable in normal enterochromaffin cells. (2000) (5)
Induction of MxA mRNA in patients with neuroendocrine tumors after interferon treatment. Lack of correlation with antitumor response. (1995) (5)
Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study. (2018) (5)
Positron emission tomography in neuroendocrine tumours. (1999) (5)
Practical guidelines for DNA-based testing in multiple endocrine neoplasia type 1. (1992) (4)
Digestive endocrine tumor management; Medical advanced disease (1999) (4)
Neuroendocrine tumours in 2012: Insights into signalling pathways could individualize therapy. (2013) (4)
Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms. (2017) (4)
Expression of growth factor peptides and adhesion molecules in endocrine pancreatic tumors. In: Frontiers of Gastrointestinal Research (1994) (4)
Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome (2016) (4)
Autoimmunity and antibodies to interferons in patients with carcinoid tumors--clinical consequences. (1994) (4)
The history and development of the gastroenteropancreatic endocrine axis. (2010) (3)
Neuroendocrine tumours of the upper gastrointestinal tract and pancreas. (1988) (3)
Circulating biomarkers in gastroentero- pancreatic neuroendocrine tumours (2011) (3)
Biochemical and immunologic diagnosis of cancer. Neuroendocrine tumors of the gastrointestinal tract and pancreas. (1987) (3)
Immunoreactive tachykinins in 24-h collections of urine from patients with carcinoid tumours: characterization and correlation with plasma concentrations. (1995) (3)
Ultrasound-guided biopsies of neuroendocrine metastases. Comparison of 0.9 and 1.2 mm biopsy-gun needle biopsies. (1993) (3)
Shared tumor antigens in colorectal carcinoma and neuroendocrine tumors. (1998) (3)
Supplementary Material for: Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer (2016) (2)
Interferon in gastrointestinal tumors-Carcinoid tumors. (1995) (2)
Assignment of the mouse homologue of a human MEN1 candidate gene, phospholipase C-beta 3 (Plcb3), to chromosome region 19B by FISH. (1995) (2)
[Tachykinins are a new family of peptides important for the diagnosis and treatment of carcinoids]. (1987) (2)
15. Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas (1987) (2)
Clinical GastroenterologyCarcinoid tumours. (1996) (2)
Circulating biomarkers of gastroenteropancreatic and lung neuroendocrine neoplasms: “The times they are a changin” (2021) (2)
Adrenocortical carcinoma - a clinical and immunohistochemical study. (1995) (2)
Circulating Biomarkers of GEP and Lung NENs: ‘The Times they are a Changin’ (2021) (2)
Molecular cloning and characterization of a cDNA encoding mouse phospholipase C-beta3. (1998) (1)
HCG-alpha and HCG-beta subunits as tumour markers during therapy in a case with so-called "non-functioning" islet cell tumour. (1981) (1)
Novel approaches in the treatment of NET (2009) (1)
Biochemical Diagnosis ofNeuroendocrine GEPTumor (1997) (1)
Carcinoid Tumours (1956) (1)
[A new diagnostic method: somatostatin receptor scintigraphy of neuroendocrine tumors]. (1992) (1)
Molecular imaging in diagnosis of neuroendocrine tumours. (2006) (1)
Interferon treatment of neuroendocrine tumour xenografts as monitored by MRI. (1994) (1)
[PET in neuroendocrine tumors]. (1998) (1)
A new pituitary protein 7B2 is increased in patients with high alpha- or beta-hCG. (1989) (1)
Somatostatin receptors in neuroendocrine tumors (2007) (1)
Neuroendocrine tumours. (2005) (1)
Risks and benefi ts of chloroquine use in anticancer strategies (2006) (1)
Ordered Phosphorylation Governs Oscillation of a Three-Protein Circadian Clock (2007) (1)
442PLong-term survival of patients with carcinoid syndrome in clinical trials of telotristat ethyl (2017) (1)
[Neuroendocrine tumors--new diagnostics and treatment]. (2010) (0)
[Management of endocrine pancreatic tumors]. (1988) (0)
Subcellular distribution of phospholipase C isoforms in rodent pancreas and gastric mucosa. (2000) (0)
Neuroendocrine tumors-Somatostatin receptors and treatment (2004) (0)
Reversal of the Malignant Phenotype of Neuroendocrine Tumor Cells by Overexpression of Vinculin. (2007) (0)
Diseases of the gut and liver : The carcinoid syndrome (2005) (0)
Nuclear Localization of 1111nAfter Intravenous Injection of [ @@@ 1]-Octreotide in Patients with Neuroendocrine Tumors (2006) (0)
Subject Index Vol. 60, 2001 (2001) (0)
Neuroendocrine tumors: recent progress ment (2011) (0)
Management of GEP-NET tumors (2012) (0)
IFN-α in advanced well-differentiated neuroendocrine tumors: the neglected drug? (2018) (0)
[Lung carcinoids--not so benign as earlier believed]. (2006) (0)
Consensus assessment : Imaging and Biomarkers in Gastroenteropancreatic 1 Neuroendocrine Tumour Disease Management (2016) (0)
[New medical therapy of neuroendocrine gastrointestinal tumors]. (1990) (0)
Carcinoid heart disease: relationship of circulating vasoactive substances (2005) (0)
disease . ultrasound in patients with carcinoid heart improves the diagnostic value of cardiac Transoesophageal echocardiography (0)
Neuroendocrine gut and pancreatic tumors (apudomas). In: Therapiekonzepte Onkologie/Therapies and Strategies in Oncology 2001, 4th edition. (2001) (0)
Mapping of the gene for multiple endocrine neoplasia type I to chromosome 11q13. (1989) (0)
SP-0570: Neuroendocrine tumours - personalised diagnosis and treatment using radiolabelled peptides (2016) (0)
Neuroendocrine tumors: recent progress in diagnosis and treatment. (2011) (0)
Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series (2021) (0)
[Endocrine gastrointestinal tumors--review, diagnosis and treatment]. (1983) (0)
Neuroendocrine tumors: From bench to bed - 25 years experience and the future (2004) (0)
662 Neuroendocrine gastrointestinal tumours - diagnosis and treatment (2003) (0)
Advances in diagnosing and treating adrenal tumors. (1990) (0)
Suprarenomas In: Therapiekonzepte Onkologie/Therapies and Strategies in Oncology 2001, 4th edition. (2001) (0)
Contents Vol. 60, 2001 (2001) (0)
Neuroendocrine GEP Tumors-Recent update on diagnosis and treatment (2005) (0)
Wolfgang; Wiedenmann, Bertram; Zheng-Pei, Zeng. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. ANNALS (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kjell E. Oberg?

Kjell E. Oberg is affiliated with the following schools: